Scholarlink

Aim <p>To assess the association between myelodysplastic syndrome and de novo bone metastasis of urothelial carcinoma.</p> Method <p>A cohort of 145,719 patients with MDS and/or UTCA included from the surveillance, epidemiology, and end results (SEER) database was conducted to assess the risk of de novo bone metastasis of UTCA (DNBM-UTCA) in patients with previously diagnosed myelodysplastic syndrome (PD-MDS). The odds ratio for developing DNBM-UTCA between MDS and non-MDS patients was estimated. Weibull accelerated failure time model was applied to evaluate the survival outcomes of patients with UTCA.</p> Results <p>Our findings suggest that PD-MDS is a powerful risk factor for DNBM-UTCA (adjusted odds ratio, 6.428; 95% CI, 1.866–16.497; <i>p</i> &lt; 0.001) and a poor prognostic factor on survival (adjusted survival time ratio, 0.485; CI, 0.338–0.695; <i>p</i> &lt; 0.001).</p> Conclusion <p>Our findings suggest that PD-MDS was associated with higher odds of DNBM-UTCA and poorer survival outcomes, which may warrant additional clinical attention during treatment decision-making. However, these findings should be considered hypothesis-generating rather than causal. Further prospective studies and mechanistic investigations are needed to better clarify the biological basis underlying the observed association between PD-MDS and bone metastasis in UTCA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical association between myelodysplastic syndrome and de novo bone metastasis in urothelial carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Zhilong Zestel Shen,
  • Gan Xu,
  • Hao Zhang,
  • Pengru Wang,
  • Xin Zhang,
  • Bo Li,
  • Jianru Xiao,
  • Wei Xu

摘要

Aim

To assess the association between myelodysplastic syndrome and de novo bone metastasis of urothelial carcinoma.

Method

A cohort of 145,719 patients with MDS and/or UTCA included from the surveillance, epidemiology, and end results (SEER) database was conducted to assess the risk of de novo bone metastasis of UTCA (DNBM-UTCA) in patients with previously diagnosed myelodysplastic syndrome (PD-MDS). The odds ratio for developing DNBM-UTCA between MDS and non-MDS patients was estimated. Weibull accelerated failure time model was applied to evaluate the survival outcomes of patients with UTCA.

Results

Our findings suggest that PD-MDS is a powerful risk factor for DNBM-UTCA (adjusted odds ratio, 6.428; 95% CI, 1.866–16.497; p < 0.001) and a poor prognostic factor on survival (adjusted survival time ratio, 0.485; CI, 0.338–0.695; p < 0.001).

Conclusion

Our findings suggest that PD-MDS was associated with higher odds of DNBM-UTCA and poorer survival outcomes, which may warrant additional clinical attention during treatment decision-making. However, these findings should be considered hypothesis-generating rather than causal. Further prospective studies and mechanistic investigations are needed to better clarify the biological basis underlying the observed association between PD-MDS and bone metastasis in UTCA.